Document is current

Article History

Received: 9 November 2021

Accepted: 24 December 2021

First Online: 24 January 2022

Declarations

:

: The trial is being performed in accordance with the World Medical Association Declaration of Helsinki and UK ethical approval has been granted by the National Research Ethics Service (East of England – Cambridge South Research Ethics Committee), part of the Health Research Authority (reference: 19/EE/0358). Each participating site is required to approve the trial via a site-specific assessor prior to entering participants into the trial. All participants are required to provide informed written consent to participate.

: Not applicable.

: This study has received funding from Microbiotica Ltd.GDS has received educational grants from Pfizer, AstraZeneca and Intuitive Surgical; consultancy fees from Pfizer, Merck, EUSA Pharma and CMR Surgical; Travel expenses from Pfizer and Speaker fees from Pfizer. BAN is a salaried employee and shareholder in Microbiotica. SH is a salaried employee of Microbiotica. DB is employed by and a shareholder of AstraZeneca. MJR is a salaried employee and shareholder in Microbiotica, as well as a shareholder in AstraZeneca. GJD has received research funding from Roche (institutional); consultancy fees/speaker honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, Merck, MSD, Novartis, Pfizer and Roche. TL is founder and CSO of Microbiotica.DJA is a paid consultant for Microbiotica and receives research funding from AstraZeneca and OpenTargets. KD is an employee of Astrazeneca. KV is an employee of Microbiotica. DB is a current employee and shareholder of Astrazeneca. PGC has received speaker fees from Bristol Myers Squibb, Merck Sharpe & Dohme, Novartis & Pierre Fabre; advisory board member for BMS and MSD, consultancy fees from Microbiotica. NAT, SJW and ND declare no competing interests.